SCLXW NASDAQ
Palo Alto, CA 94303
US
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid therapies for patients with acute and chronic pain. The company's principal product includes ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102 or SEMDEXA, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase 3 clinical trial to treat lumbosacral radicular pain; SP-103 for the treatment of low back pain, which is in Phase 2 clinical trails; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia that is in Phase 1 clinical trials. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Ma Stephen Hoi | P-Purchase | 650,000 | $1.20 | 2026-04-17 |
| Ji Henry | S-Sale | 650,000 | $1.20 | 2026-04-17 |
| Scilex Holding Co | S-Sale | 3,689,016 | $0.75 | 2025-12-26 |
| SHAH JAISIM | P-Purchase | 30,000 | $0.46 | 2024-12-18 |
| Chun Jay | A-Award | 100,000 | $0.50 | 2024-12-16 |